期刊文献+

CD44及CK18在卵巢浆液性癌中的表达及临床意义 被引量:7

The expressions and clinical significances of CD44 and CK18 in ovarian serous carcinoma
下载PDF
导出
摘要 目的:研究卵巢浆液性癌中CD44及CK18的表达及预后意义。方法:免疫组化法检测CD44及CK18蛋白在72例卵巢浆液性癌组织中的表达水平,分析其表达水平与卵巢癌临床病理指标的相关性。结果:CD44及CK18的阳性表达率分别为66.7%及100%。CD44阳性的肿瘤细胞呈团簇状分布于肿瘤组织中,这种表达模式在高级别浆液性癌中更明显。CK18表达与患者年龄、淋巴结转移有关(P分别为0.014及0.015);CD44、CK18表达与化疗效果、总生存期及无病生存期无关。卵巢浆液性癌中CD44、CK18表达无相关性。结论:CD44及CK18蛋白在卵巢浆液性癌组织中的表达能在一定程度上反映患者的预后,但与化疗效果及生存期无关。 Objective:To investigate the expression pattern and prognostic values of CD44 and CK18 in ovarian serous carcinoma. Methods:Immunohistochemical evaluation including CD44 and CK18 was performed in paraffin wax-embedded tissues of 72 cases of ovarian serous carcinoma. The expression and the relationship with clinical parameters of these markers were analyzed. Results:The positive rates were 66.7% for CD44 and 100% for CK18. Clusters of CD44^+ cells scattered in tumor tissue, and the expression pattern was more prominent in highgrade serous carcinoma. CK18 expression significantly correlated with age (P= 0. 014) and lymph node metastasis (P=0.015). CD44 and CK18 expression levels neither were correlated with chemotherapeutic effects and overall disease free survival time, nor showed any mutual relationship between each other. Conclusion: The expressions of CD44 and CK18 are correlate with the prognosis of ovarian serous carcinoma, but they are not satisfactory indicators for chemotherapeutic effects and survival time.
出处 《现代妇产科进展》 CSCD 北大核心 2016年第4期245-248,共4页 Progress in Obstetrics and Gynecology
基金 国家自然科学基金(No:81472430) “国家重大科学仪器设备开发专项”项目(No:2013YQ03065108)
关键词 卵巢浆液性癌 CD44 CK18 免疫组织化学染色 Ovarian serous carcinoma CD44 CK18 Imunohistochemistry
  • 相关文献

参考文献10

  • 1Chen R,Alvero AB, Silasi DA, et al. Inflammation, cancer and chemoresistance:taking advantage of the toll-like re- ceptor signaling pathway [ J ]. Am J Reprod Immunol, 2007,57 ( 2 ) : 93-107.
  • 2Yin G, Chen R, Alvero AB, et al. TWISTingstemness, in- flammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214 [J]. Oncogene, 2010, 29 (24) :3545-3553.
  • 3Steffensen KD, Alvero AB, Yang Y, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recur- rence in early-stage ovarian cancer [ J ]. J Oncol, 2011, 201:620523.
  • 4Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells- perspectives on current status and future directions : AACR Workshop on cancer stem cells [ J ]. Cancer Res,2006,66 (19) :9339-9344.
  • 5Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited : the cancer stem cell hypothesis [ J ]. J Clin Pharmaco1,2005,45 ( 8 ) :872-877.
  • 6Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO Classification of Tumours of Female Reproductive Organs [M]. 4th ed. Lyon:Internetional Agency for Research of Cancer, 2014 : 15-24.
  • 7Elzarkaa AA, Sabaa BE1, Abdelkhalik D, et al. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer : a prospective study [ J ]. J Cancer Res Clin 0ncol,2016[ Epub ahead of print].
  • 8王爱春,卢利娟,王昀,孙云飞,张彦,郭超,顾依群,刘爱军.CD44v6和CD24在卵巢浆液性癌组织中的表达及其临床病理意义[J].中华病理学杂志,2014,43(1):20-24. 被引量:6
  • 9Leedham SJ, Wright NA. Expansion of a mutated clone: from stem cell to turnout[ J ].J Clin Patho1,2008,61 (2) : 164-171.
  • 10Tale LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components:clinically aggressive and frequently underrecognized neoplasms [ J ]. Mod Patho1,2010,23 (6) :781-789.

二级参考文献11

  • 1Malpica A,Deavers MT,Lu K. Grading ovarian serous carcinoma using a two-tier system[J].{H}American Journal of Surgical Pathology,2004,(4):496-504.
  • 2Shi J,Zhou Z,Di W. Correlation of CD44v6 expression with ovarian cancer progression and recurrence[J].{H}BMC Cancer,2013.182.
  • 3Oktem G,Sanci M,Bilir A. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer[J].lnt J Gynecol Cancer,2012,(1):23-29.
  • 4Ikenaga N,Ohuchida K,Mizumoto K. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas[J].{H}Human Pathology,2010,(10):1466-1474.
  • 5Lim SC,Oh SH. The role of CD24 in various human epithelial neoplasias[J].{H}Pathology Research and Practice,2005,(7):479-486.
  • 6Liu M,Mor G,Cheng H. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer[J].Reprod Sci,2013,(5):605-615.
  • 7Steffensen KD,Alvero AB,Yang Y. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer[J].J Oncol,2011.620523.
  • 8Zhou DX,Liu YX,Xue YH. Expression of CD44v6 and its association with prognosis in epithelial ovarian carcinomas[J].Patholog Res Int,2012.908206.
  • 9Surowiak P,Materna V,Klak K. Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients[J].{H}Polish Journal of Pathology,2005,(2):69-74.
  • 10Surowiak P,Materna V,Kaplenko I. Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue[J].{H}International Journal of Gynecological Cancer,2006,(2):515-521.

共引文献5

同被引文献53

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部